FTD-GRN
Clinical trials for FTD-GRN explained in plain language.
Never miss a new study
Get alerted when new FTD-GRN trials appear
Sign up with your email to follow new studies for FTD-GRN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a single gene injection slow frontotemporal dementia?
Disease control OngoingThis early-stage trial tests a gene therapy called PBFT02 for frontotemporal dementia (FTD) in people with specific genetic mutations. The therapy delivers a working copy of the GRN gene directly into the brain. The study involves 30 adults and primarily checks for safety and sid…
Matched conditions: FTD-GRN
Phase: PHASE1, PHASE2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Simple blood draws could spot dementia years early
Knowledge-focused OngoingThis study tracks a protein called neurofilament light chain in the blood of 342 people who carry genetic mutations linked to frontotemporal dementia (FTD). Participants provide blood samples every three months for three years, often from home. The goal is to see if this biomarke…
Matched conditions: FTD-GRN
Sponsor: The Bluefield Project to Cure Frontotemporal Dementia • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC